SCHEMBL4735263

SCHEMBL4735263

Nc1onc2cccc(-c3ccc(NC(=O)Nc4cc(F)cc(F)c4)cc3)c12

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 19/20 0.70
KIT P10721 15/20 0.70
FLT3 P36888 15/20 0.58
ABL1 P00519 3/20 0.58
LCK P06239 3/20 0.58
FYN P06241 3/20 0.58
LYN P07948 3/20 0.58
SRC P12931 3/20 0.58
FLT1 P17948 3/20 0.58
FLT4 P35916 3/20 0.58
BLK P51451 3/20 0.58
AURKA O14965 1/20 0.58
DYRK3 O43781 1/20 0.58
ROCK2 O75116 1/20 0.58
RPS6KA5 O75582 1/20 0.58
PRKD3 O94806 1/20 0.58
MAP4K4 O95819 1/20 0.58
CHEK2 O96017 1/20 0.58
NTRK1 P04629 1/20 0.58
INSR P06213 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4736063 0.92 KDR (0.70) KDRKITFLT3ABL1LCK
SCHEMBL1382612 0.92 KDR (0.68) KDRKITFLT3ABL1LCK
SCHEMBL1383101 0.87 KDR (0.67) KDRKITFLT3ABL1LCK
SCHEMBL1382188 0.87 KDR (0.70) KDRKITFLT3ABL1LCK
SCHEMBL4739581 0.86 KDR (0.62) KDRKITFLT3ABL1LCK
SCHEMBL4740222 0.85 KDR (0.72) KDRKITFLT3LCKLYN
SCHEMBL4740182 0.85 KDR (0.72) KDRKITFLT3ABL1LCK
SCHEMBL4737316 0.85 KDR (0.68) KDRKITFLT3ABL1LCK
SCHEMBL4736275 0.85 KDR (0.71) KDRKITFLT3ABL1LCK
SCHEMBL4737823 0.84 KDR (0.70) KDRKITFLT3FLT1FLT4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008080110-A1 METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR ALCON, INC. (CH) 2008-07-03 WO claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO claimed
WO-2008080110-A1 METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR ALCON, INC. (CH) 2008-07-03 WO disclosed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 EP disclosed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 WO disclosed